Skip to main content

Table 2 Univariate and multivariate cox regressions analysis for entire study patients

From: Effects of peak time of myocardial injury biomarkers on mid-term outcomes of patients undergoing OPCABG

 

Univariate Analysis

Multivariate Analysis excluding (cTnT peak value > 0.34 mg/l)

Multivariate Analysis excluding (cTnT peak occurrence within 24 h)

Multivariate Analysis (Total)

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

Sex (n, %)

1.043 (0.564–1.928)

0.894

0.922 (0.455–1.868)

0.822

1.096 (0.550–2.185)

0.795

0.933 (0.460–1.892)

0.847

Age (y)

1.097 (1.058–1.138)

 < 0.001

1.060 (1.000–1.122)

0.048

1.076 (1.014–1.141)

0.016

1.067 (1.006–1.133)

0.031

BMI (kg/m2)

0.925 (0.850–1.007)

0.071

0.976 (0.880–1.082)

0.976

0.979 (0.883–1.084)

0.681

0.972 (0.876–1.079)

0.595

BSA (m2)

0.350 (0.069–1.775)

0.205

      

Types of CAD (n, %)

0.717 (0.473–1.088)

0.118

      

Diabetes mellitus (n, %)

1.392 (0.830–2.333)

0.210

      

Hypertension (n, %)

1.792 (0.927–3.462)

0.083

1.719 (0.855–3.455)

0.128

1.732 (0.864–3.473)

0.121

1.665 (0.826–3.358)

0.154

Cerebrovascular disease (n, %)

1.815 (1.251–2.635)

0.002

1.438 (0.952–2.172)

0.084

1.510 (1.005–2.268)

0.047

1.464 (0.972–2.205)

0.068

Peripheral vascular disease (n, %)

0.889 (0.123–6.433)

0.907

      

Combined valvular disease (n, %)

2.385 (1.169–4.864)

0.017

1.057 (0.453–2.466)

0.897

1.073 (0.456–2.525)

0.871

1.081 (0.457–2.553)

0.872

Preoperative atrial fibrillation (n, %)

1.648 (0.401–6.765)

0.488

      

Pulmonary hypertension (n, %)

3.130 (0.756–12.951)

0.115

      

Ccr (ml/min/1.73 m2)

0.968 (0.955–0.981)

 < 0.001

0.982 (0.963–1.002)

0.076

0.982 (0.963–1.000)

0.053

0.984 (0.965–1.003)

0.102

LVEF (%)

0.951 (0.918–9.984)

0.004

0.951 (0.911–0.993)

0.023

0.951 (0.909–0.994)

0.028

0.950 (0.910–0.993)

0.022

Number of diseased vessels

0.746 (0.458–1.215)

0.239

      

COPD (n, %)

1.133 (0.157–8.187)

0.901

      

Previous PCI (n, %)

0.050 (0.000–1.25*10^9)

0.806

      

NYHA (n, %)

2.160 (1.403–3.326)

 < 0.001

1.781 (1.125–2.821)

0.014

1.903 (1.199–3.019)

0.006

1.839 (1.159–2.917)

0.010

EuroSCORE II

1.695 (1.383–2.078)

 < 0.001

0.816 (0.544–1.225)

0.327

0.767 (0.508–1.156)

0.204

0.802 (0.533–1.209)

0.292

Operating time (min)

0.999 (0.995–1.003)

0.486

      

Number of bypass grafts

0.928 (0.723–1.191)

0.558

      

Number of arterial grafts

0.388 (0.239–0.628)

 < 0.001

0.964 (0.537–1.732)

0.903

1.053 (0.582–1.906)

0.865

0.977 (0.540–1.769)

0.939

Number of venous grafts

1.311 (1.037–1.659)

0.024

0.901 (0.680–1.193)

0.465

0.972 (0.734–1.286)

0.841

0.898 (0.678–1.190)

0.454

Total artery bypass grafting (n, %)

0.480 (0.150–1.538)

0.217

      

Total vein bypass grafting (n, %)

6.247 (3.077–12.683)

 < 0.001

2.855 (1.066–7.647)

0.037

3.036 (1.133–8.135)

0.027

2.833 (1.054–7.614)

0.039

CK-MB peak (mg/L)

1.001 (0.995–1.008)

0.670

      

CK-MB peak occurrence within 24 h (n, %)

0.773 (0.461–1.296)

0.328

      

CK-MB peak value > 32.00 mg/l (n, %)

1.452 (0.842–2.505)

0.180

      

cTnT peak (mg/l)

1.544 (0.936–2.546)

0.089

      

cTnT peak occurrence within 24 h (n, %)

0.243 (0.143–0.413)

 < 0.001

0.318 (0.181–0.557)

 < 0.001

  

0.362 (0.196–0.668)

0.001

cTnT peak value > 0.34 mg/L (n, %)

1.819 (1.073–3.084)

0.026

  

2.006 (1.145–3.513)

0.015

1.400 (0.753–2.604)

0.288

  1. BMI body mass index, BSA body surface area, CAD coronary artery disease, Ccr creatinine clearance rate, LVEF left ventricular ejection fraction, COPD chronic obstructive pulmonary disease, PCI percutaneous coronary intervention, NYHA New York Heart Association, EuroSCORE II European system for cardiac operative risk evaluation II, CK-MB creatine kinase myocardial band, cTnT cardiac troponin T
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us